Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658723 · ClinicalTrials.gov registry record · Phase 2
The Fibrin Patch Soft Tissue Study
A Phase 2 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT00658723: Completed Phase 2 study, sponsored by Ethicon.
NCT00658723 is a Phase 2 study that has completed, run by Ethicon. The registered enrollment target is 141 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00658723, a Phase 2 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.
Primary Outcome
Proportion of success in achieving hemostasis at 4 minutes after randomization with no re-bleeding requiring treatment during a subsequent 6-minute observation period.
Interventions
- DRUG Fibrin Pad
- DEVICE SURGICEL™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00658723 record still lists
NCT00658723 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Fibrin Pad is the first listed.
NCT00658723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00658723 about?
NCT00658723 is a clinical study titled "The Fibrin Patch Soft Tissue Study". The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.
What is the current status of trial NCT00658723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2008-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00658723?
The interventions under investigation include: Fibrin Pad (DRUG), SURGICEL™ (DEVICE).
Who is sponsoring clinical trial NCT00658723?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00658723's enrollment target sits among peer trials
141 510th of 2000 higher than 1,489 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia